← Leaderboards
Nora E Sarvetnick
University Of Nebraska Medical Center
$25,892,311
Attributed
$27,171,124
Total exposure
21
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$27,171,124 · 21
By mechanism
R01$18,041,981 · 9
U01$5,647,238 · 2
R21$1,764,512 · 3
P01$1,328,142 · 2
R56$371,250 · 1
R13$18,001 · 1
Top collaborators
- Howard S. Fox5 shared
Others in their field
Top investigators on “Autoimmunity”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$303,553,812
- Barton F Haynes · Duke University$175,178,961
- Jeffrey P Krischer · University Of South Florida$145,926,425
- Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason$84,342,024
- Mark S Anderson · University Of California, San Francisco$69,470,335
- Robert S Negrin · Stanford University$48,464,292
Research focus
AutoimmunityLaboratory MouseResponseT-LymphocyteInsulin Dependent Diabetes MellitusIsletCellsPathway InteractionsCd8b1 GeneAutoimmune DiseasesGenetically Modified AnimalsAntigensCytokinePancreatic IsletsEventInsulin-Dependent Diabetes MellitusPreventionViralBaseNod MouseFlow CytometryTherapeutic InterventionDesignDiabetes Mellitus
Grant awards (77)
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$728,669
R01 · FY2024 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$728,669
R01 · FY2022 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$728,669
R01 · FY2021 · AI · contact PI
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D$579,412
U01 · FY2021 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$733,450
R01 · FY2020 · AI · contact PI
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D$587,404
U01 · FY2020 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$157,244
R01 · FY2020 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$63,108
R01 · FY2020 · AI · contact PI
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D$724,605
R01 · FY2019 · AI · contact PI
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D$595,157
U01 · FY2019 · AI · contact PI
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D$595,601
U01 · FY2018 · AI · contact PI
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D$602,475
U01 · FY2017 · AI · contact PI
Cytokine receptor populations in human autoimmune diabetes$486,376
U01 · FY2016 · AI · contact PI
Cytokine receptor populations in human autoimmune diabetes$564,339
U01 · FY2015 · AI · contact PI
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction$506,786
R01 · FY2015 · DA
Cytokine receptor populations in human autoimmune diabetes$564,339
U01 · FY2014 · AI · contact PI
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction$529,007
R01 · FY2014 · DA
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction$579,362
R01 · FY2013 · DA
Cytokine receptor populations in human autoimmune diabetes$556,504
U01 · FY2013 · AI · contact PI
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction$558,479
R01 · FY2012 · DA
Cytokine receptor populations in human autoimmune diabetes$515,631
U01 · FY2012 · AI · contact PI
Methamphetamine and HIV: Defective immunity with CD8 T cell dysfunction$383,992
R01 · FY2011 · DA
Are IL-18 receptor-bearing CD8 T cells pathogenic in human Type 1 diabetes?$371,250
R56 · FY2011 · AI · contact PI
Mechanistic insights into B7 co-stimulation$350,099
R01 · FY2010 · AI · contact PI
Mechanistic insights into B7 co-stimulation$518,991
R01 · FY2009 · AI · contact PI
Mechanistic insights into B7 co-stimulation$203,323
R01 · FY2008 · AI · contact PI
Mechanistic insights into B7 co-stimulation$191,812
R01 · FY2008 · AI · contact PI
Mechanistic insights into B7 co-stimulation$451,272
R01 · FY2007 · AI · contact PI
Purification & Characterization of Islet Progenitors$371,909
R01 · FY2007 · DK · contact PI
Mechanistic insights into B7Co-stimulation$464,750
R01 · FY2006 · AI · contact PI
Purification & Characterization of Islet Progenitors$383,017
R01 · FY2006 · DK · contact PI
Counter-regulation In Tissue$322,589
R01 · FY2006 · DK · contact PI
Functional Tolerance to Islet Allografts$181,531
R21 · FY2006 · AI · contact PI
Immunoregulation of Flavivirus Infection$181,531
R21 · FY2006 · AI · contact PI
Purification &Characterization of Islet Progenitors$392,235
R01 · FY2005 · DK
CONSEQUENCES OF NEF EXPRESSION ON CNS PATHOLOGY$370,400
R01 · FY2005 · MH
Counter-regulation In Tissue$330,352
R01 · FY2005 · DK
Immunoregulation of Flavivirus Infection$325,325
R21 · FY2005 · AI
Functional Tolerance to Islet Allografts$325,325
R21 · FY2005 · AI
Purification &Characterization of Islet Progenitors$392,235
R01 · FY2004 · DK
Engraftment of Pancreatic Progenitors$375,400
R21 · FY2004 · DK
CONSEQUENCES OF NEF EXPRESSION ON CNS PATHOLOGY$370,400
R01 · FY2004 · MH
Counter-regulation In Tissue$330,352
R01 · FY2004 · DK
MECHANISM OF COXSACKIE VIRUS MEDIATED AUTOREACTIVITY$434,832
R01 · FY2003 · AI
Purification &Characterization of Islet Progenitors$415,990
R01 · FY2003 · DK
Engraftment of Pancreatic Progenitors$375,400
R21 · FY2003 · DK
CONSEQUENCES OF NEF EXPRESSION ON CNS PATHOLOGY$370,400
R01 · FY2003 · MH
Counter-regulation In Tissue$330,352
R01 · FY2003 · DK
MECHANISM OF COXSACKIE VIRUS MEDIATED AUTOREACTIVITY$423,326
R01 · FY2002 · AI
CONSEQUENCES OF NEF EXPRESSION ON CNS PATHOLOGY$354,600
R01 · FY2002 · MH
COUNTER REGULATION IN TISSUES$324,567
R01 · FY2002 · DK
INVOLVEMENT OF NEF IN LUNG PATHOGENESIS IN AIDS$324,100
R01 · FY2002 · HL
ISLET PROGENITOR CELLS$321,833
R01 · FY2002 · DK
Core--Histology$221,358
P01 · FY2002 · DK
Regulation of cytokine and CD8 responses in NOD mice$221,356
P01 · FY2002 · DK
FASEB Research Conference on: Autoimmunity$1
R13 · FY2002 · AI
CORE--IMMUNOLOGICAL ASSAY$0
P30 · FY2002 · MH
GENETIC IMMUNIZATION OF NOD MICE--PILOT STUDY$0
U19 · FY2002 · AI
ROLE OF CD40L IN DIABETES IN NOD MOUSE$0
U19 · FY2002 · AI
MECHANISM OF COXSACKIE VIRUS MEDIATED AUTOREACTIVITY$365,470
R01 · FY2001 · AI
CONSEQUENCES OF NEF EXPRESSION ON CNS PATHOLOGY$354,600
R01 · FY2001 · MH
INVOLVEMENT OF NEF IN LUNG PATHOGENESIS IN AIDS$324,100
R01 · FY2001 · HL
COUNTER REGULATION IN TISSUES$297,885
R01 · FY2001 · DK
ISLET PROGENITOR CELLS$296,245
R01 · FY2001 · DK
Core--Histology$221,358
P01 · FY2001 · DK
Regulation of cytokine and CD8 responses in NOD mice$221,356
P01 · FY2001 · DK
FASEB Research Conference on: Autoimmunity$18,000
R13 · FY2001 · AI
ROLE OF CD40L IN DIABETES IN NOD MOUSE$0
U19 · FY2001 · AI
GENETIC IMMUNIZATION OF NOD MICE--PILOT STUDY$0
U19 · FY2001 · AI
CORE--IMMUNOLOGICAL ASSAY$0
P30 · FY2001 · MH
MECHANISM OF COXSACKIE VIRUS MEDIATED AUTOREACTIVITY$354,825
R01 · FY2000 · AI
INVOLVEMENT OF NEF IN LUNG PATHOGENESIS IN AIDS$306,250
R01 · FY2000 · HL
COUNTER REGULATION IN TISSUES$289,212
R01 · FY2000 · DK
ISLET PROGENITOR CELLS$287,618
R01 · FY2000 · DK
Core--Histology$221,358
P01 · FY2000 · DK
Regulation of cytokine and CD8 responses in NOD mice$221,356
P01 · FY2000 · DK
CORE--IMMUNOLOGICAL ASSAY$0
P30 · FY2000 · MH